Understanding how obesity affects exercise response
Exercise Response in Humans With Obesity
Mayo Clinic · NCT05857150
This study looks at how obesity affects exercise and muscle function in adults aged 20 to 45 to see if chronic inflammation plays a role.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 20 Years to 45 Years |
| Sex | All |
| Sponsor | Mayo Clinic (other) |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT05857150 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the impact of chronic inflammation on muscle function and exercise responses in obese individuals. Participants will undergo various assessments, including treadmill and strength tests, as well as muscle and fat biopsies to gather comprehensive data. The study focuses on adults aged 20 to 45 who are classified as obese, excluding those with certain health conditions that may interfere with the results. The findings could provide insights into how obesity influences physical performance and recovery.
Who should consider this trial
Good fit: Ideal candidates are obese men and women aged 20 to 45 without significant comorbidities.
Not a fit: Patients with diabetes, chronic diseases, or those who smoke or consume excessive alcohol may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved exercise strategies and interventions for individuals with obesity.
How similar studies have performed: Other studies have explored the relationship between obesity and exercise response, suggesting potential for meaningful insights, though this specific approach may be novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Obese men and women ≥ 20 and ≤ 45 years of age. Exclusion Criteria: * Diabetes or fasting plasma glucose \>126 mg/dL * Anemia (female subjects hemoglobin of \<11 g/dl and male subjects hemoglobin \<12 g/dl) * Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment) * Renal failure (serum creatinine \> 1.5mg/dl) * Chronic active liver disease defined as aspartate aminotransferase (AST)\>144 IU/L or alanine transaminase (ALT) \>165 IU/L) * Oral warfarin group medications or history of blood clotting disorders. * Smoking * Pregnancy or breastfeeding * Alcohol consumption greater than 2 glasses/day or other substance abuse * Untreated or uncontrolled hypothyroidism * Debilitating chronic disease (at the discretion of the investigators)
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (RECRUITING)
Study contacts
- Principal investigator: Ian Lanza, PhD — Mayo Clinic
- Study coordinator: Rachel Passehl
- Email: Passehl.Rachel@mayo.edu
- Phone: 507-255-8112
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Obese